Ftse Mib
37.977,59
0,18%
DAX
22.513,42
-0,43%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
96.706,73
-0,91%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Astria Therapeutics Inc (ATXS) Astria Therapeutics Inc (ATXS) Notizie

ATXS

Astria Therapeutics (ATXS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATXS
DataOraFonteTitoloSimboloCompagnia
15/02/202500:13Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
04/02/202522:10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
04/02/202514:00Business WireAstria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:ATXSAstria Therapeutics Inc
03/02/202514:00Business WireAstria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific SessionNASDAQ:ATXSAstria Therapeutics Inc
23/01/202514:00Business WireAstria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic DermatitisNASDAQ:ATXSAstria Therapeutics Inc
13/01/202514:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXSAstria Therapeutics Inc
13/01/202514:00Business WireAstria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAENASDAQ:ATXSAstria Therapeutics Inc
07/01/202513:45Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATXSAstria Therapeutics Inc
11/12/202414:00Business WireAstria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAENASDAQ:ATXSAstria Therapeutics Inc
14/11/202423:45Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
14/11/202418:03Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATXSAstria Therapeutics Inc
13/11/202422:10Business WireAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
13/11/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
13/11/202414:00Business WireAstria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
30/10/202413:00Business WireAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
21/10/202414:00Business WireAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
16/10/202414:00Business WireEuropean Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
30/09/202414:00Business WireAstria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
27/09/202414:00Business WireAstria Therapeutics to Present at Upcoming Global Angioedema ForumNASDAQ:ATXSAstria Therapeutics Inc
19/09/202414:00Business WireAstria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology CongressNASDAQ:ATXSAstria Therapeutics Inc
30/08/202414:00Business WireAstria Therapeutics to Present at Upcoming Bradykinin SymposiumNASDAQ:ATXSAstria Therapeutics Inc
29/08/202414:00Business WireAstria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
12/08/202422:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATXSAstria Therapeutics Inc
12/08/202422:10Business WireAstria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
12/08/202422:00Business WireAstria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary AngioedemaNASDAQ:ATXSAstria Therapeutics Inc
07/08/202414:00Business WireAstria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
06/06/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
30/05/202414:00Business WireAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
24/05/202414:00Business WireAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceNASDAQ:ATXSAstria Therapeutics Inc
23/05/202414:00Business WireAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressNASDAQ:ATXSAstria Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATXS

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
MONC
Moncler
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
IP
Interpump
BIT
TITR
Telecom Italia
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
IVG
Iveco Group NV
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci